Neuronetics to Report Third Quarter 2018 Financial Results and Host Conference Call
To listen to the conference call on your telephone, please dial (877) 472-8990 for
About
Neuronetics is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, to treat adult patients with major depressive disorder, or MDD, that have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.
Investor Contact:
Westwicke Partners
443-213-0501
ir@neuronetics.com
Media Contact:
Vault Communications
610-455-2742
Lbrown@vaultcommunications.com